Medtronic plc (NYSE:MDT) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Ca ...

Medtronic plc (NYSE:MDT) 42nd Annual Cowen Health Care Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: 42nd Annual Cowen Health Care Conference Call - **Date**: March 7, 2022 - **Participants**: - Karen Parkhill - Executive Vice President and Chief Financial Officer - Josh Jennings - Cowen & Company Key Points Industry and Market Trends - **Fiscal Q4 Trends**: February was expected to be the lightest month, with modest underlying procedure acceleration. Greater acceleration is anticipated in March and April [4][3] - **Impact of Russia/Ukraine Conflict**: Medtronic has minimal exposure, with revenue from these regions being less than 1% of total revenue. No manufacturing or direct material suppliers are located in these countries [5] Financial Performance and Guidance - **Supply Chain and Inflation**: No changes in supply chain guidance since the fiscal third quarter earnings call. Inflationary pressures are expected to continue into FY 2023, impacting EPS growth [6][32] - **EPS Growth Expectations**: FY 2023 is expected to be challenging, with EPS growth anticipated but not exceeding revenue growth. Currency fluctuations and acquisition dilution are expected to impact EPS by a few hundred basis points [33][32] Product Development and Regulatory Updates - **Diabetes Franchise**: Ongoing discussions with the FDA regarding the warning letter and the approval of key diabetes products (780G and Guardian 4). Progress is being made on remediation efforts [9][11] - **Renal Denervation**: Confidence in the approval of renal denervation therapy based on previous studies. The ON MED trial results are expected to be shared at a major cardiovascular meeting [16][20] - **Hugo Surgical System**: Positive feedback from surgeons on the Hugo system's features. The system is currently in limited market release, with high demand and ongoing data collection for regulatory filings [21][23] Strategic Initiatives - **Portfolio Review**: Medtronic is intensively reviewing its portfolio to optimize business units and drive sustainable revenue growth. Decisions regarding potential divestitures or spinouts are expected within the fiscal 2023 timeframe [36][40] - **Macro Challenges**: Ongoing challenges include staffing shortages, supply chain issues (particularly in semiconductors and resins), and inflation. These factors are expected to persist into FY 2023 and potentially FY 2024 [43][46] Acquisitions - **Intersect ENT Acquisition**: The acquisition is progressing well, with expectations for closing soon [48] Additional Insights - **Long-term Growth Commitment**: Medtronic remains committed to its long-range plan, with expectations for a return to organic revenue growth post FY 2023 [35][34] - **Investment in R&D**: Continued investment in R&D is crucial for future growth, despite current economic challenges [33][32] This summary encapsulates the key discussions and insights from the Medtronic conference call, highlighting the company's strategic direction, financial outlook, and product development efforts.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Medtronic plc (NYSE:MDT) Q3 2022 Earnings Conference Call February 22, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Sean Salmon - Executive Vice President and President, Cardiovascular and Diabetes Bob White - Executive Vice President and President, Medical Surgical Brett Wall - Executive Vice President and President, Neuroscience Conference Call Participants R ...

Medtronic plc Conference Call Summary Company Overview - **Company**: Medtronic plc (NYSE: MDT) - **Event**: 40th Annual J.P. Morgan Healthcare Conference - **Date**: January 10, 2022 Key Points Industry and Company Transformation - Medtronic is undergoing a significant transformation aimed at accelerating growth and improving competitiveness, initiated 18 months ago [5][36] - The company has restructured into 20 operating units, enhancing focus and decision-making, resulting in over 70% of units now holding or winning market share, up from 35% [5][22] Financial Performance and Market Position - Medtronic has achieved over 180 product approvals in the last 12 months and continues to invest heavily in R&D and M&A [7][26] - The company expects to maintain a long-term growth profile of over 5% top-line growth and over 8% bottom-line growth [50][53] Pipeline and Product Development - Key pipeline updates include: - **Symplicity Renal Denervation**: Delays in trials but expected to tap into a multibillion-dollar market opportunity [10] - **Hugo Robotic-Assisted Surgery System**: Adjusted revenue expectations due to supply chain issues, but high customer interest remains [11] - **Diabetes Products**: Facing regulatory challenges but ongoing remediation efforts are in place [12] - The company is optimistic about its robust pipeline, which is not reliant on a few products [28] Operational Challenges and Responses - The pandemic has impacted operations, with 14 out of 20 businesses reaching pre-COVID revenue levels, but staffing shortages remain a concern [13] - The strengthening U.S. dollar is expected to create currency headwinds, estimated at $30 million to $40 million for Q3 [14][15] Quality and Safety Initiatives - Medtronic is prioritizing patient safety and quality improvements following several recalls, with a focus on enhancing operational excellence [24][48] - A new capital allocation framework is in place to better manage investments across its portfolio [25] Strategic Acquisitions - The acquisition of Affera is aimed at enhancing Medtronic's cardiac ablation portfolio, with a transaction value of nearly $1 billion [30] - The company is also focusing on strategic customer relationships to drive growth [19] ESG Commitment - Medtronic is committed to being a leader in ESG practices, focusing on innovation, patient safety, and diversity [35] Future Outlook - The company is confident in its ability to deliver double-digit total shareholder returns, driven by a strong product pipeline and market leadership across multiple segments [34][36] Additional Insights - The transformation includes cultural changes to foster a more competitive environment, with a focus on accountability and performance-based incentives [17][20] - Medtronic is leveraging technology development centers to enhance innovation and reduce costs across its business units [18] This summary encapsulates the key points discussed during the Medtronic conference call, highlighting the company's strategic direction, operational challenges, and future growth prospects.

Medtronic plc (NYSE:MDT) Q2 2022 Earnings Conference Call November 23, 2021 8:00 AM ET Company Participants Ryan Weispfenning - Vice President & Head of Investor Relations Geoffrey Martha - Chairman & Chief Executive Officer Karen Parkhill - Chief Financial Officer Sean Salmon - EVP & President of the Cardiovascular and Diabetes Operating Unit Bob White - EVP & President of Medical Surgical Portfolio Brett Wall - EVP & President of Neuroscience Portfolio Conference Call Participants Robbie Marcus - JPMorga ...